Pretoria, 10 December 2020 — TB Alliance welcomes the Wits Health Consortium and the South African National Department of Health (DoH)’s announcement of an initiative to provide a new, shorter treatment regimen for people affected with highly drug-resistant forms of tuberculosis (TB). Funded by the United States Agency for International Development, a new clinical access program (CAP) will enroll 400 people in South Africa for treatment with a three-drug, six-month, all-oral regimen of bedaquiline, pretomanid and linezolid (known as the BPaL regimen) that has been shown to demonstrate a favorable outcome in 90% of patients.¹ This treatment was developed by TB Alliance and studied in its pivotal Nix-TB trial, which was also conducted in South Africa.

NEW YORK (October 30, 2020) — At the Prix Galien Awards Ceremony on Thursday, October 29, The Galien Foundation named pretomanid the Best Pharmaceutical Agent of 2019.

LIFT-TB to increase treatment completion rates for drug-resistant TB, focusing on seven high-burden Southeast and Central Asian countries that shoulder about 1 in 5 TB case.

Pretomanid, developed by the non-profit TB Alliance, has received EU marketing authorisation in combination regimen with bedaquiline and linezolid in adults with XDR-TB or treatment-intolerant/non-responsive MDR-TB.

Pretomanid is only the third new anti-tuberculosis (TB) drug developed specifically for drug-resistant forms of the disease to be approved in more than 40 years

Approval comes as a result of Mylan’s global collaboration with non-profit drug development partner TB Alliance

Guilford, Conn., June 2, 2020 - InveniAI^® LLC, a global leader pioneering the application of artificial intelligence (AI) and machine learning (ML) to transform innovation across drug discovery and development, is pleased to announce a strategic partnership with TB Alliance, a non-profit organization dedicated to the discovery, development, and delivery of better, faster-acting and affordable tuberculosis (TB) drugs. TB Alliance will make use of InveniAI’s AI and machine learning platform, AlphaMeld^®, to identify and accelerate transformative therapies for the management, treatment, and cure of TB, which remains the world’s top infectious disease killer.

NEW YORK (January 16, 2020)—Non-profit drug developer TB Alliance has granted Shenyang Hongqi Pharmaceuticals Co., Ltd. (“Hongqi Pharma”), a wholly-owned subsidiary of Shanghai Fosun Pharmaceutical (Group) Co., Ltd. (“Fosun Pharma”, stock code: 600196.SH; 02196.HK) a license to market the anti-TB medicine pretomanid as part of the three-drug “BPaL” regimen. Hongqi has agreed to commercialize the anti-tuberculosis (TB) medicine in the People’s Republic of China.

MSF, TAG and TB CAB raised a number of outstanding medical and research questions regarding pretomanid and the regimen BPaL.

NEW YORK and MUMBAI (October 28, 2019)—Non-profit drug developer TB Alliance has granted Macleods Pharmaceuticals Limited a non-exclusive license to manufacture the anti-TB drug pretomanid as part of the three-drug “BPaL” regimen. Pending regulatory approvals, Macleods has agreed to commercialize the anti-tuberculosis (TB) medicine in approximately 140 countries and territories.

Pretomanid receives FDA approval in combination regimen with bedaquiline and linezolid for people with XDR-TB or treatment-intolerant/non-responsive MDR-TB.